$0.40
+0.00 (+0.75%)
Open$0.41
Previous Close$0.40
Day High$0.41
Day Low$0.40
52W High$6.23
52W Low$0.28
Volume—
Avg Volume866.9K
Market Cap5.92M
P/E Ratio—
EPS$-1.97
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+10,031.5% upside
Current
$0.40
$0.40
Target
$40.83
$40.83
$24.77
$40.83 avg
$47.84
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 731.6K | 1.39M | 2.02M |
| Net Income | -50,659,034 | -86,662,479 | 234.8K |
| Profit Margin | -6,925.2% | -6,578.9% | 11.6% |
| EBITDA | -56,050,956 | -101,213,473 | 368.8K |
| Free Cash Flow | — | — | 168.2K |
| Rev Growth | -47.4% | -47.4% | +14.4% |
| Debt/Equity | 0.33 | 0.33 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |